TY - JOUR
T1 - Allelic Imbalance at an 8q24 Oncogenic SNP is Involved in Activating MYC in Human Colorectal Cancer
AU - Sugimachi, Keishi
AU - Niida, Atsushi
AU - Yamamoto, Ken
AU - Shimamura, Teppei
AU - Imoto, Seiya
AU - Iinuma, Hisae
AU - Shinden, Yoshiaki
AU - Eguchi, Hidetoshi
AU - Sudo, Tomoya
AU - Watanabe, Masahiko
AU - Tanaka, Junichi
AU - Kudo, Shinei
AU - Hase, Kazuo
AU - Kusunoki, Masato
AU - Yamada, Kazutaka
AU - Shimada, Yasuhiro
AU - Sugihara, Kenichi
AU - Maehara, Yoshihiko
AU - Miyano, Satoru
AU - Mori, Masaki
AU - Mimori, Koshi
N1 - Funding Information:
ACKNOWLEDGMENTS We thank T. Shimooka, M. Kasagi, T. Kawano, and S. Kouno for their technical assistance. This work was supported in part by the following grants and foundations: CREST, Japan Science and Technology Agency; Japan Society for the Promotion of Science Grant-in-Aid for Scientific Research; and the Funding Program for Next Generation World-Leading Researchers (LS-094).
Publisher Copyright:
© 2014, Society of Surgical Oncology.
PY - 2014
Y1 - 2014
N2 - Background: The rs6983267 at 8q24.21 has been established as a significant cancer-related single nucleotide polymorphism (SNP). The risk allele showed similarity to the binding site of transcription factor TCF4/LEF1 that activates transcription of MYC. However, little is known about the role of this SNP in increasing MYC activity in colorectal cancers (CRCs).Methods: The genotypes of rs6983267 in peripheral blood and primary cancers, MYC activity and copy number (CN) alteration were examined in 107 CRCs. Next, we plotted the number of cancers cell lines exhibiting specific G/T genotypes in 746 cancer cell lines of the Sanger Institute database. Then we validated the relationship between the 8q24 SNP status and clinicopathologic parameters in 68 CRCs with loss of heterozygosity (LOH).Results: The MYC module activity was activated by either transcription in the risk allele (G) or by amplification in the non-risk allele (T). Then, we confirmed that the CN amplification dominantly occurred in the non-risk allele, whereas CN neutral LOH, which indicated uniparental disomy (UPD) was more frequently observed for the risk allele. Finally, we confirmed that risk allele dominant cases, either by amplification or by UPD, indicated a more malignant clinical phenotype than non-risk allele dominant cases.Conclusions: The development of CRC requires MYC activation through retention of the risk allele, or amplification of the non-risk allele at the oncogenic SNP in the site of primary tumor.
AB - Background: The rs6983267 at 8q24.21 has been established as a significant cancer-related single nucleotide polymorphism (SNP). The risk allele showed similarity to the binding site of transcription factor TCF4/LEF1 that activates transcription of MYC. However, little is known about the role of this SNP in increasing MYC activity in colorectal cancers (CRCs).Methods: The genotypes of rs6983267 in peripheral blood and primary cancers, MYC activity and copy number (CN) alteration were examined in 107 CRCs. Next, we plotted the number of cancers cell lines exhibiting specific G/T genotypes in 746 cancer cell lines of the Sanger Institute database. Then we validated the relationship between the 8q24 SNP status and clinicopathologic parameters in 68 CRCs with loss of heterozygosity (LOH).Results: The MYC module activity was activated by either transcription in the risk allele (G) or by amplification in the non-risk allele (T). Then, we confirmed that the CN amplification dominantly occurred in the non-risk allele, whereas CN neutral LOH, which indicated uniparental disomy (UPD) was more frequently observed for the risk allele. Finally, we confirmed that risk allele dominant cases, either by amplification or by UPD, indicated a more malignant clinical phenotype than non-risk allele dominant cases.Conclusions: The development of CRC requires MYC activation through retention of the risk allele, or amplification of the non-risk allele at the oncogenic SNP in the site of primary tumor.
UR - http://www.scopus.com/inward/record.url?scp=84942567612&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84942567612&partnerID=8YFLogxK
U2 - 10.1245/s10434-013-3468-6
DO - 10.1245/s10434-013-3468-6
M3 - Article
C2 - 24390711
AN - SCOPUS:84942567612
SN - 1068-9265
VL - 21
SP - 515
EP - 521
JO - Annals of Surgical Oncology
JF - Annals of Surgical Oncology
IS - 4
ER -
